Skip to main content

Table 3 Real-world effectiveness of treatment as assessed by the treating physician (n = 41/42*)

From: Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry

Variable Response, % (n/N) [95% CI]
Overall 70.7 (29/41) [54.5 to 83.9]
Probable aspergillosis 71.8 (28/39) [55.1 to 85.0]
Proven aspergillosis 50.0 (1/2) [37.4 to 74.5]
Combination therapy** 80.0 (4/5) [28.4 to 99.5]
Monotherapy 69.4 (25/36) [51.9 to 83.7]
First-line therapy*** 63.6 (7/11) [30.8 to 89.1]
Second-line therapy 73.3 (20/30) [54.1 to 87.7]
Neutropenic status at start of caspofungin therapy  
Neutrophilic granulocytes < 500/uL 71.4 (20/28) [51.3 to 86.8]
Neutrophilic granulocytes ≥ 500/uL 69.2 (9/13) [38.6 to 90.9]
Risk factors****  
   Allogeneic HSCT 87.5 (7/8) [47.3 to 99.7]
   Acute renal disease 80.0 (4/5) [28.4 to 99.5]
   Neutropenia at hospitalization 70.4 (19/27) [49.8 to 86.2]
   Active cancer 69.2 (27/39) [52.4 to 83.0]
   Immunosuppressive therapy 68.4 (26/38) [51.3 to 82.5]
   Prior colonization with fungi 66.7 (4/6) [22.3 to 95.7]
   Autologous HSCT 50.0 (2/4) [6.8 to 93.2]
  1. * No data were available for one lung transplant patient with proven aspergillosis (A. fumigatus), who had received triple combination therapy (amphotericin B, caspofungin, voriconazole). If this patient is regarded as a failure, the response rate for all 42 patients is: favorable response, 29/42 patients (69%; 95% CI 53 to 82%).
  2. ** Combination of caspofungin with amphotericin B desoxycholate (two patients), with fluconazole (one patient), with posaconazole (one patient), with amphotericin B desoxycholate plus voriconazole (one patient). Note, if the patient described in * is included in the effectiveness population and (post hoc) counted as a failure, the response rate for patients with combination therapy is 66.7% (4/6) and the 95% confidence interval is 22.2% to 95.7%.
  3. *** All patients receiving caspofungin first line were on monotherapy.
  4. **** Multiple answers possible.